Daicel Corporation (DACHF)

Market Cap	2.67B +16.7%
Revenue (ttm)	3.69B +0.4%
Net Income	262.40M -26.1%
EPS	0.99 -23.2%
Shares Out	n/a
PE Ratio	10.19
Forward PE	n/a
Dividend	0.40 (4.70%)
Ex-Dividend Date	Mar 30, 2026

Volume	125
Average Volume	163
Open	8.44
Previous Close	8.43
Day's Range	8.44 - 8.44
52-Week Range	8.43 - 8.44
Beta	0.29
RSI	n/a
Earnings Date	Feb 5, 2026

About Daicel

Daicel Corporation engages in the materials, medical/healthcare, smart, safety, and engineering plastics businesses in Japan and internationally. The company offers medical/healthcare products, including BELLOCEA S7, a spherical cellulose acetate particle; FLAVOCELL S-Equol; Urolithin A; polyglycerols; konjac ceramide; excipients for foods; chiral columns and reagents; and Actranza lab, as well as separation and analytical services. It also provides performance films, solvents for electronic materials, cycloaliphatic epoxies, polymers for photo...

• Industry: Specialty Chemicals
• Sector: Materials
• Founded: 1919
• Employees: 11,178
• Stock Exchange: OTCMKTS
• Ticker Symbol: DACHF

Financial Performance

In fiscal year 2025, Daicel's revenue was 586.53 billion, an increase of 5.10% compared to the previous year's 558.06 billion. Earnings were 49.48 billion, a decrease of -11.38%.

Financial numbers in JPY